Serotonin Norepinephrine Inhibitor Market, By Application (Depression, Anxiety Disorders, Chronic Pain, Diabetic Neurotherapy, and others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region (North America, Euro

Serotonin Norepinephrine Inhibitor Market, By Application (Depression, Anxiety Disorders, Chronic Pain, Diabetic Neurotherapy, and others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

A Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) is a class of medications typically used as antidepressants in the treatment of major depressive disorder (MDD) and other mood disorders. SNRIs work by inhibiting the reuptake of two important neurotransmitters in the brain — serotonin and norepinephrine. By blocking the reabsorption (reuptake) of these neurotransmitters into the neurons, SNRIs increase the levels and enhance the actions of serotonin and norepinephrine in the brain. Serotonin is involved in mood, emotion, and sleep. Norepinephrine is related to alertness and energy. Increasing the amount of these neurotransmitters improves communication between the brain cells and can have a positive impact on mood and emotion, which is beneficial for patients suffering from depression.

Some commonly prescribed SNRIs include:-

• Venlafaxine (Effexor XR)
• Duloxetine (Cymbalta)
• Desvenlafaxine (Pristiq)
• Levomilnacipran (Fetzima)

SNRIs are also approved to treat other conditions such as anxiety disorders, chronic pain conditions like fibromyalgia, and neuropathic pain associated with diabetes.

Market Dynamics:

Rising number of people suffering from depression globally is a major factor driving the market growth of the global serotonin norepinephrine inhibitor market. According to World Health Organization (WHO), over 5.0% of the worldwide population suffers from depression. This number is expected to increase in the near future, due to various factors such as increasing social isolation and stressful work environment, which leads to the development of depression. The increase in the demand for effective treatment of depression is also driving the growth of this market. The emergence of COVID-19 pandemic increased the unemployment rate in several countries and has led to financial instability. This has resulted in a decrease in the household income, which is causing stress and anxiety among people which in turn is increasing the demand for antidepressant drugs.

On the other hand, side effects associated with the drugs is expected to hamper the market growth of the global serotonin norepinephrine inhibitor market.

Key features of the study:

• This report provides in-depth analysis of the global serotonin norepinephrine inhibitor market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global serotonin norepinephrine inhibitor market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Pfizer Inc., Eli Lilly and Company, Allergan Plc., AstraZeneca Plc., Forest Laboratories Inc., Johnson & Johnson, Lundbeck A/S, Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Wyeth Pharmaceuticals Inc., and Zydus Cadila Healthcare Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global serotonin norepinephrine inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global serotonin norepinephrine inhibitor market

Detailed Segmentation:

• Global Serotonin Norepinephrine Inhibitor Market, By Application
• Depression
• Anxiety Disorders
• Chronic Pain
• Diabetic Neuropathy
• Others
• Global Serotonin Norepinephrine Inhibitor Market, By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Serotonin Norepinephrine Inhibitor Market, By Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa
• Top Companies in the Global Serotonin Norepinephrine Inhibitor Market
• Pfizer Inc.
• Eli Lilly and Company
• Allergan Plc.
• AstraZeneca Plc.
• Forest Laboratories Inc.
• Johnson & Johnson
• Lundbeck A/S
• Merck & Co., Inc.
• Otsuka Pharmaceutical Co., Ltd.
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• Torrent Pharmaceuticals Ltd.
• Wyeth Pharmaceuticals Inc.
• Zydus Cadila Healthcare Ltd.